Reckitt Benckiser Group (OTCMKTS:RBGLY) Raised to Strong-Buy at UBS Group

UBS Group upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) to a strong-buy rating in a report released on Wednesday morning, Zacks.com reports.

Separately, JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an overweight rating to a neutral rating in a report on Thursday, August 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Reckitt Benckiser Group has an average rating of Hold and an average target price of $7,400.00.

Reckitt Benckiser Group Price Performance

Shares of RBGLY opened at $12.08 on Wednesday. The stock has a 50 day moving average price of $11.38 and a two-hundred day moving average price of $11.33. Reckitt Benckiser Group has a 52 week low of $10.24 and a 52 week high of $15.03.

Reckitt Benckiser Group Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Monday, September 23rd. Investors of record on Monday, August 5th will be paid a $0.1915 dividend. The ex-dividend date of this dividend is Monday, August 5th.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.